Skip to content
NeuroTechGuide

Beacon Biosignals buys home sleep testing provider Snap Diagnostics

The EEG company says the deal more than doubles its patient reach and gives it a route to bring EEG-based home sleep tests to patients from 2027.

In briefIndustryNon-invasive

Beacon Biosignals has acquired Snap Diagnostics, a home sleep apnea testing provider serving patients in all 50 US states, the company announced on October 22. The price was not disclosed. Snap ships tests to patients, scores and interprets them, and bills Medicare and commercial insurers directly. It will keep its name as a Beacon subsidiary.

Beacon, which uses EEG and machine learning to measure sleep and brain activity in drug trials, says the deal more than doubles its patient reach. It plans to bring EEG-enabled home sleep testing to more patients starting in 2027. Its longer-term aim of detecting early signs of neurodegenerative disease through sleep testing remains a company goal, not an established use.

Learn more: EEG · Beacon Biosignals

Share:XLinkedInBlueskyEmail

More news